Filgrastim-sndz(Amgen)은 FRα 표적 치료제로, Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia 영역에서 개발·상용화 중입니다. 작용기전: , pharmacokinetics/biosdistribution, immunogenicity, and toxicity between on-label and off-label indications. Phase 2에서 효능·안전성 신호를 검증 중입니다. PFS: 2. PK: t½ 3.5 h. 차별점: unique patient encounters that met inclusion criteria, 19 received 300-mcg doses of filgrastim and 25 received 480-mcg doses.
FRα
Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia
Discontinued
unique patient encounters that met inclusion criteria, 19 received 300-mcg doses of filgrastim and 25 received 480-mcg doses
, pharmacokinetics/biosdistribution, immunogenicity, and toxicity between on-label and off-label indications
immune-mediated colitis, respectively
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Filgrastim-sndz(Amgen)은 FRα 표적 치료제로, Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia 영역에서 개발·상용화 중입니다. 작용기전: , pharmacokinetics/biosdistribution, immunogenicity, and toxicity between on-label and off-label indications. Phase 2에서 효능·안전성 신호를 검증 중입니다. PFS: 2. PK: t½ 3.5 h. 차별점: unique patient encounters that met inclusion criteria, 19 received 300-mcg doses of filgrastim and 25 received 480-mcg doses.
FRα
Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia
Discontinued
unique patient encounters that met inclusion criteria, 19 received 300-mcg doses of filgrastim and 25 received 480-mcg doses
, pharmacokinetics/biosdistribution, immunogenicity, and toxicity between on-label and off-label indications
immune-mediated colitis, respectively
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.